Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Technology Officer, Dr Matt Johnson, will be presenting new data for Affimer research tools and diagnostics reagents at the Biomarkers and Precision Medicine Congress in San Diego on the 12 October 2018.
Dr Johnson will be presenting recent data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays.
The data that Dr Johnson will present shows that immunoassays built using Affimers perform as well as, and in many cases better than, equivalent assays built using antibodies. These data are critical in driving the adoption of the new Affimer technology in a huge market that is dominated by antibodies.
In the second part of his presentation, Dr Johnson will speak about an innovative class of Affimers that captures antibodies but only when the antibodies are bound to their own targets. This offers a route to improving an important type of diagnostic test to have a more specific and clearer result. The commercial potential for this class of Affimer is significant.